Third, PCa uniquely offers a validated surface biomarker, prostate‐specific membrane antigen (PSMA), that is overexpressed in advanced disease and provides both diagnostic and therapeutic targeting opportunities for nanoparticles [14, 15]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.